GPhA Eyeing Alternative Terms For "Follow-On" Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic industry trade group hopes to reach consensus on nomenclature in time for an FDA/DIA workshop on follow-on proteins in February. GPhA opposes use of the terms "follow-on," "biosimilar" and "biocomparable."